Paul Nisson

012617-my-picThe Biomedical Research Institute (BRI) has NIH and CDC supported basic and applied research programs in Tropical Public Health. Our basic research program is focused on understanding the immunopathology and the clinical sequelae from human infection with Schistosoma haematobium. BRI’s mission is to develop a point of care diagnostic for S. haematobium and S. mansoni which account for 99% of the 300 million cases of schistosomiasis globally.

Our Schistosomiasis Resource Center, supported by NIAID, provides life cycle reagents (parasites, infected snails and rodents) to researchers throughout the world at no cost to the researcher. We distribute over 200 schistosomiasis research products through BEI at the American Type Culture Collection. BEI ATCC

BRI’s Biorepository is supported by the NIH  and private clients and is a member of the AIDS Clinical Trials Network Group (ACTG); we store more than 6 million clinical samples in our Biorepository to support the ACTG. We also support a number of other clients from the public and private sector in our facility.

Dr. Nisson has been the Executive Director of the Biomedical Research Institute in Rockville, MD since July of 2013. Before that time, he has held a number of senior management and technical positions in the public and private sector.

BRI is an Illinois nonprofit research company that was incorporated in Chicago in 1948 and operated a research facility in Madison, WI until 1974 under the name, American Foundation for Biological Research (AFBR), where projects in agricultural and hematological cryobiology were the focus. AFBR started doing business as Biomedical Research Institute (BRI) in the late 1960s in Rockville, MD.